<DOC>
	<DOCNO>NCT00604578</DOCNO>
	<brief_summary>This study test whether pioglitazone hydrochloride ( Actos ( Registered Trademark ) Registered Trademark ) effective treat patient asthma respond standard therapy . Experiments show drug , use treat patient diabetes , may effective treat asthma . People 18 75 year age asthma least a1 year whose symptom well control high dos inhale corticosteroid without long-acting bronchodilator may eligible study . Candidates screen breathe test , allergy skin test , chest x-ray , electrocardiogram ( ECG ) , echocardiogram ( ultrasound test heart ) , blood test , DEXA scan ( x-ray measure bone thickness ) make sure eligible study . Then , participant undergo test procedure follow study phase : Phase 1 Participants give device measure record lung function asthma symptom home morning night 4 week start study medication . Lung function also measure clinic visit inhale bronchodilator medicine . Before start study medication , participant sputum induction ( sputum collection test ) . For test , participant inhale salt-water mist ask collect sputum plastic cup . Phase II Participants randomly select receive either pioglitazone hydrochloride placebo ( look-alike pill active ingredient ) day 10 week . They return clinic 2 week repeat test do Phase 1 monitor reaction study drug placebo . If problem , amount medication increase , return follow-up evaluation every 2 week 8 week . Pulmonary function test , sputum collection DEXA scan repeat 10 week medication . Phase III Patients return follow-up 1 month stop medication placebo monitor asthma .</brief_summary>
	<brief_title>Pioglitazone Hydrochloride ( Actos ( Registered Trademark ) ) Treat Asthma</brief_title>
	<detailed_description>New therapy need patient asthma suboptimally control standard measure . Pioglitazone hydrochloride ( Actos [ R ] ) highly selective potent agonist peroxisome proliferator-activated receptor-gamma ( PPAR gamma ) . Studies murine model allergic asthma show PPAR gamma-agonists down-regulate allergen-mediated airway inflammation airway hyperresponsiveness . This protocol randomize , placebo-controlled , double-blind , parallel-group ( phase II ) pilot study efficacy safety pioglitazone treatment patient allergic asthma reversible airflow obstruction persistently symptomatic despite therapy high dos inhale corticosteroid without long-acting Beta 2-agonists . The primary end-point study change airflow obstruction , measure post-bronchodilator FEV1 . Secondary end-points include index airway inflammation , airflow obstruction , airway hyperreactivity , asthma symptom .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients 18 75 year age , male female , diagnosis asthma least one year . Patients must reversible airflow obstruction define positive methacholine bronchoprovocation challenge positive response inhale bronchodilator . Patients must treat EPR3 Step 5 therapy ( high dose ( great equal 440 ucg/day ) fluticasone inhaler equivalent dose another inhaled corticosteroid ) without inhale longacting beta2agonist ) least 3 month . Patients must meet EPR3 criterion well control asthma . The EPR3 definition well control asthma include follow feature week ( unless otherwise indicate ) : daytime asthma symptom great 2 days/week , limitation activity , nocturnal symptom awaken great 2 times/month , need reliever/rescue treatment great 2 days/week , PEF FEV ( 1 ) less 80 % predict . Prebronchodilator FEV ( 1 ) great equal 55 % predict postbronchodilator FEV ( 1 ) great equal 60 % predict . During 6 week prior enrollment , patient stable asthma define absence unscheduled health care visit asthma care unchanged use asthma maintenance therapy . Additional criterion disease stability include absence hospitalization asthma need course oral corticosteroid precede 3 month . Research subject must positive skin test common aeroallergen , dust mite , cat , short ragweed , cockroach , grass prior history severe allergy anaphylaxis . Chest radiograph without evidence pulmonary disease , asthma . Left ventricular ejection fraction great equal 50 % echocardiogram . For woman childbearing potential , negative pregnancy test within 2 week prior study willingness adhere reliable birth control method study . Subjects history dermatologic cancer may include cancerfree least 5 year prior enrollment . EXCLUSION CRITERIA : A known history hypersensitivity pioglitazone . Maintenance asthma therapy oral corticosteroid , xolair ( antiIgE ) , methotrexate , cytoxan , gold salt , cyclosporine . Cigarette smoke within past 3 month prior history great 10 cumulative packyears . Viral bacterial upper respiratory tract infection within 6 week prior screen visit . Investigational therapy indication within 1 month prior screen visit . History lung disease asthma ( i.e. , COPD , sarcoidosis ) . History diabetes mellitus , insulin secrete tumor , symptomatic hypoglycemia . HIV known immunodeficiency . History congestive heart failure . Preexisting edema ( 2 plus great ) . Hemoglobin le 12 gm/dl male less 11 gm/dl female . History liver disease abnormal liver function test great 2 time upper limit normal . History inflammatory bowel disease . History cancer ( dermatologic cancer ) . History drug alcohol abuse . Use following medication , interact pioglitazone : Gemfibrizol ( Lopid ) Atazanivir ( Reyataz ) Ritonavir ( Norvir ) Rifampin ( Rifampicin ) Carbamzepine ( Tegretol ) Phenobarbital ( Luminal ) Phenytoin ( Dilantin ) Rifapentine ( Priftin ) Secobarbital ( Seconal ) Amiodarone ( Cordarone , Pacerone ) Palitaxel ( Taxol ) Replaglinide ( Prandine ) Ketoconazole ( Nizoral ) Atorvastatin ( Lipitor ( Registered Trademark ) ) Nifedipine ER ( Adalat CC ) Any condition , investigator 's opinion , place patient undue risk complication pioglitazone therapy . Dexa bone scan ( T score 1 SD ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 30, 2009</verification_date>
	<keyword>Pioglitazone</keyword>
	<keyword>Asthma</keyword>
	<keyword>Peroxisome Proliferator-Advanced Receptor Gamma</keyword>
	<keyword>Airflow Obstruction</keyword>
	<keyword>Airway Inflammation</keyword>
</DOC>